Traumatic Brain Injuries Treatment Market Research Report - Global Forecast till 2023

Global Traumatic Brain Injuries (TBI) Treatment Market Research Report: by treatment (immediate emergency care, medications (diuretics, analgesic and others), surgery), by end-users (hospitals, neurologist, independent pharmacies and others)—Forecast till 2023

ID: MRFR/Pharma/5374-HCR | February 2021 | Region: Global | 90 pages

Market Scenario:


Global traumatic brain injuries treatment market is expected to rise steadily at a CAGR of 5.1% during forecast period of 20182023.


Traumatic brain injuries treatment (TBI) is an interruption in the normal function of the brain. It is a serious public health problem and is the leading cause of brain injury with at least 1.7 million people sustaining such injury every year. Traumatic brain injuries contribute to a substantial number of death and permanent disability every year. About 52,000 people dies of this injury which are commonly caused by car accident, falls, blunts force trauma, violent assaults and sporting injuries. An estimated 2.8 million people suffers from traumatic brain injuries treatment annually in United States of which 50,000 dies and 282,000 are hospitalized. Every day 153 people in United States die from TBI injury. 


Numerous factors propelling the growth of this market are rising number of road traffic collisions and increasing number of aging populations. Whereas growing interests in research activities on diagnosis of TBI and new pipeline of drugs are further boosting the growth of traumatic brain injuries treatment market.


Despite the drivers, factors such as high cost of treatment and the use of monitoring devices may hinder the growth of market.


Segmentation:


Global traumatic brain injuries treatment market is further segmented into treatment types and end-users.


Based on treatment types the market is segmented into immediate emergency care, medications and surgery. On basis of medication global traumatic brain injuries treatment market is further sub-segmented into diuretics, anti-seizure drugs, coma-inducing drugs, anti-anxiety agent, anti-depressants, anti-psychotics, analgesic, anti-convulsant and anti-coagulants. Based on surgery, TBI market is further sub-segmented into removing clotted blood (hematomas), repairing skull fractures, bleeding in the brain, opening a window in the skull, rehabilitation.


On basis of end-users global traumatic brain injuries treatment market is further segmented into hospitals, neurologist, rehabilitative centre treatment, independent pharmacies and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The traumatic brain injuries treatment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. US account for the largest share of traumatic brain injuries treatment market.  


The European traumatic brain injuries treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The traumatic brain injuries treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The traumatic brain injuries treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players:


Some of the key players in the global traumatic brain injuries treatment market are Neuren Pharmaceuticals Ltd., Oxygen Biotherapeutics Inc, TEVA Pharmaceutical Industries Ltd, Ischemic, Grace Laboratories LLC. Cognosci, Medicortex, Amarantus BioScience Holdings, Aldagen, NeuroScience Pharmaceuticals, Targacept. BioDirection, Inc., QuesGen Systems, Inc., BrainScope Company, Inc., Neural Analytics, Inc, Oculogica, BrainScope Company, Inc, Silver Creek, Pharmaceuticals Inc, Stemedica Cell Technologies Inc, Banayan Biomarkers Inc, Vasopharm GmbH, Zimmer Biomet.


Regional Market Summary
Global Traumatic Brain Injuries Treatment Market Share (%), by Region, 2017


Source: Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American association of neurological surgeon


Geographically, the Americas is anticipated to dominate the global traumatic brain injuries treatment market. The market growth in this region is attributed to the increasing incidences of road accident in this region. Moreover, increasing investment by government in research and development of drug pipeline in treatment of TBI has boosted the market growth in this region. According to the Health United States Report 2016, 2.8 million people sustains TBI annually of which 50,000 dies and 282,000 are hospitalized and about 2.5 million nearly 90% are treated and released from emergency department. TBI contributes to 30% injury related death in United States. 


Europe is expected to be the second largest market in the globe owing to the increasing aging population and increasing prevalence of TBI in low- and middle-income countries. According to the data collected by journal of neurosurgery the overall incidence of TBI per 100,000 people was highest in Europe and about 95% of population suffered from TBI injury due to increasing incidences of road traffic collisions.


Asia-Pacific is anticipated to be the fastest growing market owing to the growing prevalence of road traffic collision in the developing countries. Whereas Southeast Asian and Western Pacific region experiences the highest burden of TBI disease.


The proportion of TBI resulting from road traffic collision was found greatest in Africa and Southeast Asia.


Global Traumatic brain injuries treatment Market, by Treatment



  • Immediate emergency care

  • Medications

    • Diuretics

    • Anti-seizure drugs

    • Coma-inducing drugs

    • Anti-anxiety agent

    • Anti-depressants

    • Anti-psychotics

    • Analgesic

    • Anti-convulsant

    • Anti-coagulants



  • Surgery

    • Removing clotted blood (hematomas)

    • Repairing skull fractures

    • Bleeding in the brain

    • Opening a window in the skull

    • Rehabilitation




Global Traumatic brain injuries treatment Market, by End User



  • Hospitals

  • Neurologist

  • Independent pharmacies

  • Rehabilitative centre treatment

  • Other


Global Traumatic brain injuries treatment Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • South America



  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe



  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Republic of Korea

    • Rest of Asia Pacific



  • Middle East & Africa

    • Middle East

    • Africa




Global Traumatic brain injuries treatment Market, by Key Players



  • Zimmer Biomet

  • Neuren Pharmaceuticals Ltd.

  • Oxygen Biotherapeutics Inc

  • TEVA Pharmaceutical Industries Ltd

  • Ischemic

  • Grace Laboratories LLC

  • Cognosci

  • Medicortex

  • Amarantus BioScience Holdings

  • Aldagen

  • NeuroScience Pharmaceuticals

  • Targacept

  • BioDirection, Inc.

  • QuesGen Systems, Inc.

  • BrainScope Company, Inc.

  • Neural Analytics, Inc

  • Oculogica

  • BrainScope Company, Inc

  • Silver Creek Pharmaceuticals Inc

  • Stemedica Cell Technologies Inc

  • Banayan Biomarkers Inc

  • Vasopharm GmbH


Intended Audience



  • Manufacturers and Suppliers

  • Neurologist hospitals and clinics

  • Laboratories and Associations



Frequently Asked Questions (FAQ) :


Traumatic Brain Injuries Treatment (TBI) Market would record a 5.1% CAGR during the forecast period of 2018 to 2023.

High treatment cost and inclusion of monitoring devices can impact the growth of the Traumatic Brain Injuries Treatment (TBI) Market.

Global traumatic brain injuries treatment would be driven by the Americas.

US would lead the American Traumatic Brain Injuries Treatment (TBI) Market.

Asia Pacific would be the fastest-growing Traumatic Brain Injuries Treatment (TBI) Market.

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Traumatic Brain Injury Treatment Market , by Treatment

6.1 Introduction

6.2 Immediate emergency care

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

6.3 Medications

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

6.3.1 Diuretics

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

6.3.2 Anti-seizure drugs

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

6.3.3 Coma-inducing drugs

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

6.3.4 Anti-Anxiety Agent

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

6.3.5 Anti-Depressants

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

6.3.6 Anti-Psychotics

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

6.3.7 Analgesic

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

6.3.8 Anti-Convulsants,

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

6.3.9 Anti-Coagulants

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

6.4 Surgery

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

6.4.1 Removing clotted blood (hematomas)

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

6.4.2 Repairing skull fractures

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

6.4.3 Bleeding in the brain

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

6.4.5 Opening a window in the skull

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

6.4.6 Rehabilitation

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023
Chapter 7. Global Traumatic Brain Injury Treatment Market , by End-User

7.1 Introduction

7.2 Hospitals

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

7.3 Neurologist

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

7.4 Independent Pharmacies

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

7.5 Rehabilitative Center Treatment

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

7.6 Other

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

Chapter 8. Global Traumatic Brain Injury Treatment Market , by Region

8.1 Introduction

8.2 Americas

8.2.1 North America

8.2.1.1 US

8.2.1.2 Canada

8.2.2 South America

8.3 Europe

8.3.1 Western Europe

8.3.1.1 Germany

8.3.1.2 France

8.3.1.3 Italy

8.3.1.4 Spain

8.3.1.5 UK

8.3.1.6 Rest of Western Europe

8.3.2 Eastern Europe

8.4 Asia-Pacific

8.4.1 Japan

8.4.2 China

8.4.3 India

8.4.4 Australia

8.4.5 South Korea

8.4.6 Rest of Asia-Pacific

8.5 Middle East & Africa

8.5.1 Middle East

8.5.2 Africa

Chapter 9 Company Landscape

9.1 Introduction

9.2 Market Share Analysis

9.3 Key Development & Strategies

Chapter 10. Company Profiles

10.1 Zimmer Biomet

10.1.1 Company Overview

10.1.2 Product Overview

10.1.3 Financials Overview

10.1.4 Key Developments

10.1.5 SWOT Analysis

10.2 Neuren Pharmaceuticals Ltd

10.2.1 Company Overview

10.2.2 Product Overview

10.2.3 Financial Overview

10.2.4 Key Developments

10.2.5 SWOT Analysis

10.3 Oxygen Biotherapeutics Inc

10.3.1 Company Overview

10.3.2 Product Overview

10.3.3 Financial Overview

10.3.4 Key Development

10.3.5 SWOT Analysis

10.4 TEVA Pharmaceutical Industries Ltd

10.4.1 Company Overview

10.4.2 Product Overview

10.4.3 Financial Overview

10.4.4 Key Development

10.4.5 SWOT Analysis

10.5 Ischemic

10.5.1 Company Overview

10.5.2 Product Overview

10.5.3 Financial overview

10.5.4 Key Developments

10.5.5 SWOT Analysis

10.6 Grace Laboratories LLC

10.6.1 Company Overview

10.6.2 Product Overview

10.6.3 Financial Overview

10.6.4 Key Developments

10.6.5 SWOT Analysis

10.7 Cognosci

10.7.1 Overview

10.7.2 Product Overview

10.7.3 Financial Overview

10.7.4 Key Developments

10.7.5 SWOT Analysis

10.8 Medicortex

10.8.1 Overview

10.8.2 Product Overview

10.8.3 Financials

10.8.4 Key Developments

10.8.5 SWOT Analysis

10.7 Amarantus BioScience Holdings

10.7.1 Overview

10.7.2 Product Overview

10.7.3 Financials

10.7.4 Key Developments

10.7.5 SWOT Analysis

10.8 Aldagen

10.8.1 Overview

10.8.2 Product Overview

10.8.3 Financials

10.8.4 Key Developments

10.8.5 SWOT Analysis

10.11 NeuroScience Pharmaceuticals

10.91 Overview

10.92 Product Overview

10.93 Financials

10.94 Key Developments

10.95 SWOT Analysis

10.10 Targacept

10.10.1 Overview

10.10.2 Product Overview

10.10.3 Financials

10.10.4 Key Developments

10.10.5 SWOT Analysis

10.13 BioDirection, Inc

10.13.1 Overview

10.13.2 Product Overview

10.13.3 Financials

10.13.4 Key Developments

10.13.5 SWOT Analysis

10.14 QuesGen Systems, Inc

10.14.1 Overview

10.14.2 Product Overview

10.14.3 Financials

10.14.4 Key Developments

10.14.5 SWOT Analysis

10.15 BrainScope Company, Inc

10.15.1 Overview

10.15.2 Product Overview

10.15.3 Financials

10.15.4 Key Developments

10.15.5 SWOT Analysis

10.16 Neural Analytics, Inc

10.16.1 Overview

10.16.2 Product Overview

10.16.3 Financials

10.16.4 Key Developments

10.16.5 SWOT Analysis

10.17 Oculogica

10.17.1 Overview

10.17.2 Product Overview

10.17.3 Financials

10.17.4 Key Developments

10.17.5 SWOT Analysis

10.18 BrainScope Company, Inc

10.18.1 Overview

10.18.2 Product Overview

10.18.3 Financials

10.18.4 Key Developments

10.18.5 SWOT Analysis

10.19 Silver Creek Pharmaceuticals Inc

10.19.1 Overview

10.19.2 Product Overview

10.19.3 Financials

10.19.4 Key Developments

10.19.5 SWOT Analysis

10.20 Stemedica Cell Technologies Inc

10.20.1 Overview

10.20.2 Product Overview

10.20.3 Financials

10.20.4 Key Developments

10.20.5 SWOT Analysis

10.21 Banayan Biomarkers Inc

10.21.1 Overview

10.21.2 Product Overview

10.21.3 Financials

10.21.4 Key Developments

10.21.5 SWOT Analysis

10.22 Vasopharm GmbH

10.22.1 Overview

10.22.2 Product Overview

10.22.3 Financials

10.22.4 Key Developments

10.22.5 SWOT Analysis
Chapter 11 MRFR Conclusion

11.1 Key Findings

11.1.1 From CEO’s View point

11.1.2 Unmet Needs of the Market

11.2 Key Companies to Watch

11.3 Predictions for the Traumatic Brain Injury Treatment Market

Chapter 12. Appendix


LIST OF TABLES

Table 1 Global Traumatic Brain Injury Treatment Market Synopsis, 2018–2023

Table 2 Global Traumatic Brain Injury Treatment Market Estimates and Forecast, 2018–2023

(USD Million)

Table 3 Global Traumatic Brain Injury Treatment Market , by Region, 2018–2023 (USD Million)

Table 4 Global Traumatic Brain Injury Treatment Market , by Treatment , 2018–2023 (USD Million)

Table 5 Global Traumatic Brain Injury Treatment Market , by End-User, 2018–2023 (USD Million)

Table 6 North America: Traumatic Brain Injury Treatment Market , by Treatment , 2018–2023 (USD Million)

Table 7 North America: Traumatic Brain Injury Treatment Market , by End-User, 2018–2023

(USD Million)

Table 8 US: Traumatic Brain Injury Treatment Market , by Treatment , 2018–2023 (USD Million)

Table 9 US: Traumatic Brain Injury Treatment Market , by End-User, 2018–2023 (USD Million)

Table 10 Canada: Traumatic Brain Injury Treatment Market ,by Treatment , 2018–2023

(USD Million)

Table 11 Canada: Traumatic Brain Injury Treatment Market , by End-User, 2018–2023

(USD Million)

Table 12 South America: Traumatic Brain Injury Treatment Market , by Treatment , 2018–2023 (USD Million)

Table 13 South America: Traumatic Brain Injury Treatment Market , by End-User, 2018–2023 (USD Million)

Table 14 Europe: Traumatic Brain Injury Treatment Market , by Treatment , 2018–2023

(USD Million)

Table 15 Europe: Traumatic Brain Injury Treatment Market , by End-User, 2018–2023

(USD Million)

Table 16 Western Europe: Traumatic Brain Injury Treatment Market , by Treatment , 2018–2023 (USD Million)

Table 17 Western Europe: Traumatic Brain Injury Treatment Market , by End-User, 2018–2023 (USD Million)

Table 20 Eastern Europe: Traumatic Brain Injury Treatment Market , by Treatment , 2018–2023 (USD Million)

Table 19 Eastern Europe: Traumatic Brain Injury Treatment Market , by End-User, 2018–2023 (USD Million)

Table 20 Asia-Pacific: Traumatic Brain Injury Treatment Market , by Treatment , 2018–2023

(USD Million)

Table 21 Asia-Pacific: Traumatic Brain Injury Treatment Market , by End-User, 2018–2023

(USD Million)

Table 22 Middle East & Africa: Traumatic Brain Injury Treatment Market , by Treatment, 2018-2023 (USD Million)

Table 23 Middle East & Africa: Traumatic Brain Injury Treatment Market , by End-User, 2018–2023 (USD Million)



LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Traumatic Brain Injury Treatment Market

Figure 3 Segmentation Market Dynamics for Global Traumatic Brain Injury Treatment Market

Figure 4 Global Traumatic Brain Injury Treatment Market Share, by Treatment , 2017

Figure 5 Global Traumatic Brain Injury Treatment Market Share, by End-User, 2017

Figure 6 Global Traumatic Brain Injury Treatment Market Share, by Region, 2017

Figure 7 North America: Traumatic Brain Injury Treatment Market Share, by Country, 2017

Figure 8 Europe: Traumatic Brain Injury Treatment Market Share, by Country, 2017

Figure 9 Asia-Pacific: Traumatic Brain Injury Treatment Market Share, by Country, 2017

Figure 10 Middle East & Africa: Traumatic Brain Injury Treatment Market Share, by Country, 2017

Figure 11 Global Traumatic Brain Injury Treatment Market : Company Share Analysis, 2017 (%)

Figure 12 Zimmer Biomet: Key Financials

Figure 13 Zimmer Biomet: Segmental Revenue

Figure 14 Zimmer Biomet: Geographical Revenue

Figure 15 Neuren Pharmaceuticals Ltd: Key Financials

Figure 16 Neuren Pharmaceuticals Ltd: Segmental Revenue

Figure 17 Neuren Pharmaceuticals Ltd: Geographical Revenue

Figure 20 Oxygen Biotherapeutics Inc: Key Financials

Figure 19 Oxygen Biotherapeutics Inc: Segmental Revenue

Figure 20 Oxygen Biotherapeutics Inc: Geographical Revenue

Figure 21 TEVA Pharmaceutical Industries Ltd : Key Financials

Figure 22 TEVA Pharmaceutical Industries Ltd: Segmental Revenue

Figure 23 TEVA Pharmaceutical Industries Ltd : Geographical Revenue

Figure 24 Ischemic: Key Financials

Figure 25 Ischemic: Segmental Revenue

Figure 26 Ischemic. Geographical Revenue

Figure 27 Grace Laboratories LLC: Key Financials

Figure 28 Grace Laboratories LLC: Segmental Revenue

Figure 29 Grace Laboratories LLC: Geographical Revenue

Figure 30 Cognosci: Key Financials

Figure 31 Cognosci: Segmental Revenue

Figure 32 Cognosci: Geographical Revenue

Figure 33 Medicortex: Key Financials

Figure 34 Medicortex: Segmental Revenue

Figure 35 Medicortex: Geographical Revenue

Figure 36 Amarantus BioScience Holdings: Key Financials

Figure 37 Amarantus BioScience Holdings: Segmental Revenue

Figure 38 Amarantus BioScience Holdings: Geographical Revenue

Figure 39 Aldagen: Key Financials

Figure 40 Aldagen: Segmental Revenue

Figure 41 Aldagen: Geographical Revenue

Figure 42 NeuroScience Pharmaceuticals : Key Financials

Figure 43 NeuroScience Pharmaceuticals : Segmental Revenue

Figure 44 NeuroScience Pharmaceuticals : Geographical Revenue

Figure 45 Targacept: Key Financials

Figure 46 Targacept: Segmental Revenue

Figure 47 Targacept: Geographical Revenue

Figure 48 BioDirection, Inc: Key Financials

Figure 49 BioDirection, Inc: Segmental Revenue

Figure 50 BioDirection, Inc: Geographical Revenue

Figure 51 QuesGen Systems, Inc: Key Financials

Figure 52 QuesGen Systems, Inc: Segmental Revenue

Figure 53 QuesGen Systems, Inc: Geographical Revenue

Figure 54 BrainScope Company, Inc, Inc: Key Financials

Figure 55 BrainScope Company, Inc, Inc: Segmental Revenue

Figure 56 BrainScope Company, Inc, Inc: Geographical Revenue

Figure 57 Neural Analytics, Inc, Inc: Key Financials

Figure 58 Neural Analytics, Inc, Inc: Segmental Revenue

Figure 59 Neural Analytics, Inc, Inc: Geographical Revenue

Figure 60 Oculogica, Inc: Key Financials

Figure 61 Oculogica, Inc: Segmental Revenue

Figure 62 Oculogica, Inc: Geographical Revenue

Figure 63 BrainScope Company, Inc: Key Financials

Figure 64 BrainScope Company, Inc: Segmental Revenue

Figure 65 BrainScope Company, Inc: Geographical Revenue

Figure 66 Silver Creek Pharmaceuticals Inc: Key Financials

Figure 67 Silver Creek Pharmaceuticals Inc: Segmental Revenue

Figure 68 Silver Creek Pharmaceuticals Inc: Geographical Revenue

Figure 69 Stemedica Cell Technologies Inc: Key Financials

Figure 70 Stemedica Cell Technologies Inc: Segmental Revenue

Figure 71 Stemedica Cell Technologies Inc: Geographical Revenue

Figure 72 Banayan Biomarkers Inc: Key Financials

Figure 73 Banayan Biomarkers Inc: Segmental Revenue

Figure 74 Banayan Biomarkers Inc: Geographical Revenue

Figure 75 Vasopharm GmbH: Key Financials

Figure 76 Vasopharm GmbH: Segmental Revenue

Figure 77 Vasopharm GmbH: Geographical Revenue